Picture Fairtec GmbH Worldwide Event Solutions 650x65px

News > All

Total search results: 17104 | Ordered by Source (descending)
next pagenext page 1 2 3 ... 170 171 172  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
Zealand Pharma A/S. (12/12/11). "Press Release: Zealand Pharma Announces Registration of Capital Increase and New Articles of Association Following Warrant Exercise". Copenhagen. 2011-12-12
Zealand Pharma A/S. (11/3/11). "Press Release: Zealand Pharma Announces that a European Regulatory Application Has Been Submitted for Lyxumia (lixisenatide) by Its Partner Sanofi, as a Novel Once-daily GLP-1 Agonist for Type-2 Diabetes". Copenhagen. 2011-11-03
Zealand Pharma A/S. (11/3/10). "Press Release: Zealand Pharma Publishes Prospectus and Sets Indicative Price Range for Initial Public Offering". 2010-11-03
Zealand Pharma A/S. (11/15/13). "Press Release: Interim Report for the First Nine Months of 2013 (un-audited)". Copenhagen. 2013-11-15
Zealand Pharma A/S. (10/9/15). "Press Release: Zealand Meets Development Milestone in Collaboration with Boehringer Ingelheim". Copenhagen. 2015-10-09
Zealand Pharma A/S. (10/22/19). "Press Release: Zealand Pharma Expands Its Peptide Platform with Acquisition of Encycle Therapeutics". Copenhagen. 2019-10-22
Zealand Pharma A/S. (10/22/15). "Press Release: Zealand to Attend Three International Investor Healthcare Conferences and Host Capital Markets Days in November". Copenhagen. 2015-10-22
Zealand Pharma A/S. (10/15/10). "Press Release: Positive Phase I Data for ZP1848 in Crohn’s Disease. Study Findings Demonstrate Significant Increase in Citrulline Levels Indicating Enhanced Gut Function". Copenhagen. 2010-10-15
Zealand Pharma A/S. (10/1/18). "Press Release: Zealand Pharma Expands Leadership Team and Appoints Marino Garcia as Senior Vice President of Corporate & Business Development". Copenhagen. 2018-10-01
Zealand Pharma A/S. (1/4/13). "Press Release: Zealand Pharma Appoints New Chief Operating Officer. Agneta Svedberg Named as Successor to Senior Vice President and Chief Operating Officer, John Hyttel, Who Is Retiring". Copenhagen. 2013-01-04
Zavante Therapeutics, Inc.. (3/30/16). "Press Release: Zavante Therapeutics Closis $45 Million Series A Financing in Support of U.S. Development for a First-in-Class Injectable Antibiotic". San Diego, CA. 2016-03-30
Zavante Therapeutics, Inc.. (10/9/15). "Press Release: Zavante Announces New Company Formation and Initial Financing". San Diego, CA. 2015-10-09
Zambon Group. (7/25/19). "Press Release: Zambon Completes Transformational Acquisition of Breath Therapeutics". Milan. 2019-07-25
Zambon Group. (6/19/14). "Press Release: Zambon Italy and Mundipharma Signed a Co-Marketing and Distribution Agreement". 2014-06-19
Zafgen, Inc.. (7/10/14). "Press Release: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Parder-Willi Syndrome". Cambridge, MA. 2014-07-10
Yumab GmbH. (7/22/19). "Press Release: Yumab Announces New Research and Collaboration Agreement with Merck". Braunschweig. 2019-07-22
Yukin Therapeutics S.A.S.. (6/4/19). "Press Release: Yukin Therapeutics Raises €3.3 million to Develop New Cancer Treatments". Sophia Antipolis. 2019-06-04
Ysios Capital. (9/24/18). "Press Release: Ysios Capital Strengthens Its Team with the Appointment of Guillem Laporta as Principal and Two New Venture Partners". Barcelona. 2018-09-24
Ysios Capital. (3/19/14). "Press Release: Ysios Capital Begins Fundraising for Ysios Biofund II. New Fund to Back Disruptive Life Sciences Company in Europe and US". Barcelona. 2014-03-19
Ysios Capital. (10/18/16). "Press Release: Ysios Capital Raises €126,4 m ($140 m) for Its Second Fund, Ysios Biofund II Innvierte". Barcelona. 2016-10-18
Ysios Capital Partners. (12/01/2011). "Press Release: Ysios Capital Partners and “la Caixa” Lead MedLumics €3.5million/$4.7million Series A Financing". Madrid. 2011-12-01
Ysios Capital Partners. (09/21/2010). "Press Release: Ysios Capital Partners Leads €5 Million Series A Financing of Sabirmedical". Barcelona. 2010-09-21
Ysios Capital Partners. (09/13/2011). "Press Release: Ysios Capital Partners Leads €29.2million Series D Financing of AM-Pharma". Barcelona. 2011-09-13
Ysios Capital Partners. (05/29/2012). "Press Release: Cristina Garmendia Returns to Ysios Capital as Partner". Barcelona. 2012-05-29
Yposkesi. (7/9/18). "Press Release: Yposkesi Appoints Dr. Fraser Wright as Senior Advisor". Corbeil-Essonnes. 2018-07-09
Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes. 2019-06-05
Ynsect S.A.. (3/4/14). "Press Release: Ynsect Raises 1.8 Million Euro in Series A Funding to Develop Insect Biorefineries". 2014-03-04
Ynsect S.A.. (2/21/19). "Press Release: Ÿnsect Raises $125m to Become World Leader in Alternative Protein". Paris & London. 2019-02-21
Ynsect S.A.. (12/17/14). "Press Release: Ynsect Raised 5.5 Million Euros During Its Second Funding Campaign". 2014-12-17
XstalBio Ltd.. (8/9/13). "Press Release: XstalBio Awarded a SMART Grant to Focus on Development of Mucosal Targeted Vaccines for Livestock Parasites". 2013-08-09
XstalBio Ltd.. (8/12/13). "Press Release: XstalBio Launches CentuRecon to Accelerate the Delivery of Biologic Drugs at High Concentration". Glasgow. 2013-08-12
XstalBio Ltd.. (4/17/14). "Press Release: TSB Grant for XstalBio’s Platform Vaccine Technology – Tablet Vaccines". 2014-04-17
Xoma Ltd.. (11/9/11). "Press Release: Xoma Expands Gevokizumab (XOMA 052) Program". Berkeley, CA. 2011-11-09
Xoma Corporation. (8/25/17). "Press Release: Xoma Announces Transformational License Agreements for Gevokizumab and Its IL-1 beta Intellectual Property Portfolio". Berkeley, CA. 2017-08-25
XO1 Ltd.. (9/17/13). "Press Release: Global Thought-leaders in Anticoagulation Join X01 Scientific Advisory Board, Richard Mason Appointed CEO". Cambridge. 2013-09-17
XO1 Ltd.. (6/17/13). "Press Release: XO1 Ltd Raises $11 Million from Index Ventures to Develop the »Holy Grail« of Anticoagulant Drugs". Cambridge. 2013-06-17
Xlife Sciences AG. (11/4/19). "Press Release: Xlife Siences AG. New Project in the Portfolio". Zurich. 2019-11-04
XL-protein GmbH. (7/26/17). "Press Release: Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation Technology to Develop Long-Acting Asparaginase Product Candidates". Freising. 2017-07-26
XL-protein GmbH. (6/25/13). "Press Release: XL-protein and Generium Sign Broad Therapeutic License and Collaboration Agreement to Develop PASylated Therapeuticas for the Russian Federation". Freising & Moscow. 2013-06-25
XL-protein GmbH. (4/18/13). "Press Release: High Yield with ESETEC and PASylation. Wacker Biotech and XL-protein Produce More than Four Grams per Liter of Fab Antibody Fragment with Prolonged Plasma Half-life". Munich, Jena & Freising. 2013-04-18
XL-protein GmbH. (2/12/15). "Press Release: XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals Using its PASylation Technology". Freising. 2015-02-12
XL-protein GmbH. (10/21/14). "Press Release: Yeda and XL-protein Sign Business Collaboration Agreement to Commercialize PASylated Interferon Superagonist". Freising & Rehovot. 2014-10-21
XL-protein GmbH. (1/9/18). "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation® Technology". Freising. 2018-01-09
Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva. 2017-01-05
Xention Ltd.. (5/13/15). "Press Release: Xention Introduces Metrion Biosciences, a Specialist Ion Channel Screening Business". Cambridge. 2015-05-13
Xenikos B.V.. (5/24/16). "Press Release: Xenikos B.V. to Introduce Immunotherapy T-Guard to Potential Pharmaceutical Partners at BIO International Convention 2016". Nijmegen. 2016-05-24
Xenikos B.V.. (5/15/18). "Press Release: Dutch Company Xenikos Secures USD 30 Million in Series B Financing". Nijmegen. 2018-05-15
Xenetic Biosciences plc. (5/10/13). "Press Release: Commencement of Phase II with MyeloXen, the Novel Vaccine for Multiple Sclerosis". 2013-05-10
Xencor, Inc.. (4/4/12). "Press Release: Xencor Receives Second Milestone Payment from Boehringer Ingelheim under Antibody Technology License Agreement". Monrovia, CA. 2012-04-04
Xencor, Inc.. (2/5/19). "Press Release: Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech". Monrovia, CA. 2019-02-05
Xencor, Inc.. (1/7/19). "Press Release: Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody". Monrovia, CA. 2019-01-07
Xeltis. (12/2/14). "Press Release: Xeltis Closes Euro 27 Million / USD 34 Million Series B Financing". Zürich. 2014-12-02
Xeltis AG. (2/2/16). "Press Release: Xeltis Appoints New CFO". 2016-02-02
Xeltis AG. (12/17/15). "Press Release: Xeltis Extends Series B Financing to €30M, Signing off Transformational Year". Zurich. 2015-12-17
Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven. 2017-11-15
Xeltis AG. (1/31/17). "Press Release: FDA Gives Xeltis Go Ahead to Begin Trials in the USA". 2017-01-31
Xceleron. (6/13/11). "Press Release: Xceleron Announces Key Board and Executive Appointments. Increasing Demand from Big Pharma for Greater R&D Productivity". York. 2011-06-13
X-Biotix Therapeutics, Inc.. (7/1/19). "Press Release: X-Biotix Therapeutics Joins Antimicrobials Working Group". Washington, DC. 2019-07-01
Wyatt Technology Corporation. (11/16/10). "Press Release: Wyatt Technology Instrumentation Used against Bacteriophage Infections in Dairy Production". Santa Barbara, CA. 2010-11-16
WuXi PharmaTech. (8/23/11). "Press Release: WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD". Shanghai. 2011-08-23
WuXi NextCode. (9/7/17). "Press Release: WuXi NextCode Completes $240 Million Series B Financing". Shanghai, Cambridge, MA & Reykjavik. 2017-09-07
WuXi AppTec. (4/15/16). "Press Release: WuXi AppTec Acquires Crelux". Munich. 2016-04-15
Wren Therapeutics Ltd.. (1/22/19). "Press Release: Wren Therapeutics Completes £18 Million Series A Financing". Cambridge. 2019-01-22
Wise S.r.l.. (5/25/17). "Press Release: Wise Srl Raises EUR 6.5 Million for Clinical Validation of Novel Neuroelectrodes for Brain Monitoring and Spinal Cord Stimulation". Milan & Berlin. 2017-05-25
Wilson Therapeutics AB. (4/16/14). "Press Release: Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson’s Disease". Stockholm. 2014-04-16
Wilson Therapeutics AB. (12/14/17). "Press Release: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease". 2017-12-14
Wilex AG. (9/6/13). "Press Release: Nuclea Biotechnologies Inc. Acquires Wilex Inc. and Extends Their Cooperation with Wilex AG. Nuclea Purchased All Shares of Wilex Inc. (Oncogene Science)". Munich & Pittsfield, MA & Cambridge, MA. 2013-09-06
Wilex AG. (9/27/16). "Press Release: Subsidiary Heidelberg Pharma Contracts Suisse CDMO Celonic for Antibody Cell Line Development and Antibody Production". Munich. 2016-09-27
Wilex AG. (9/2/13). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs License Agreement for the Development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche". Munich. 2013-09-02
Wilex AG. (9/19/16). "Press Release: Wilex AG – Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center". Munich. 2016-09-19
Wilex AG. (8/7/13). "Press Release: Wilex Starts Clinical Phase I Trial with PI3K Inhibitor WX-037". Munich. 2013-08-07
Wilex AG. (8/4/10). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. 2010-08-04
Wilex AG. (8/17/10). "Press Release: Wilex AG. Mandatory Takeover Offer from dievini Hopp BioTech Has Ended". Munich. 2010-08-17
Wilex AG. (8/12/15). "Press Release: Wilex AG Announces Discontinuation of Collaboration between Its Subsidiary Heidelberg Pharma and Roche [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. 2015-08-12
Wilex AG. (7/29/10). "Press Release: Wilex AG Recommends Shareholders Not to Accept the Mandatory Offer of dievini Hopp BioTech holding GmbH % Co. KG". Munich. 2010-07-29
Wilex AG. (7/2/13). "Press Release: Burrill Securities Supports Wilex in Exploring Financing Partners". Munich. 2013-07-02
Wilex AG. (7/19/10). "Press Release: Wilex AG Resolves Rights Issue Using Authorised Capital". Munich. 2010-07-19
Wilex AG. (7/15/14). "Press Release: Wilex Publishes Half-yearly Financial Report 2014". Munich. 2014-07-15
Wilex AG. (7/15/14). "Press Release: Wilex AG Successfully Completes Capital Reduction. Reverse 4:1 Share Split Reduces Number of Outstanding Shares from 31.3 Million to 7.8 Million". Munich. 2014-07-15
Wilex AG. (7/15/10). "Press Release: Wilex AG Receives Tender Offer for a Mandatory Takeover Bid by dievini Hopp BioTech holding". Munich. 2010-07-15
Wilex AG. (7/14/15). "Press Release: Wilex Publishes Half-yearly Financial Report". Munich. 2015-07-14
Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich. 2017-07-13
Wilex AG. (7/12/12). "Press Release: Wilex Announces Results of Successful First Half Year 2012". Munich. 2012-07-12
Wilex AG. (7/11/13). "Press Release: Wilex Publishes Half-yearly Financial Report 2013". Munich. 2013-07-11
Wilex AG. (7/10/13). "Press Release: UCB Gets Access to Rights for an Antibody Programme from Wilex for Non-oncology Indications". Munich & Brussels. 2013-07-10
Wilex AG. (6/30/14). "Press Release: Wilex and RedHill Biopharma Enter into an Exclusive License Agreement for Mesupron". Munich & Tel Aviv. 2014-06-30
Wilex AG. (6/2/16). "Press Release: Wilex AG Announces Change on the Executive Management Board". Munich. 2016-06-02
Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich. 2017-06-19
Wilex AG. (6/14/12). "Press Release: Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial". Munich. 2012-06-14
Wilex AG. (5/3/10). "Press Release: Final Phase II Data of Mesupron Confirm Impressive Increase in Overall Survival of Patients with Pancreatic Cancer". Munich. 2010-05-03
Wilex AG. (4/8/15). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. 2015-04-08
Wilex AG. (4/25/16). "Press Release: Wilex AG Successfully Completes Capital Increase". Munich. 2016-04-25
Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich. 2017-04-24
Wilex AG. (4/14/14). "Press Release: Wilex Published 3-Month Financial Reports 2014". Munich. 2014-04-14
Wilex AG. (4/14/10). "Press Release: Wilex Publishes 3-Month Financial Report 2010 and Reports Improved Results for the Period". Munich. 2010-04-14
Wilex AG. (4/14/10). "Press Release: Presentation 3-Month Financial Report. 14 April 2010". Munich. 2010-04-14
Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich. 2017-04-12
Wilex AG. (4/12/12). "Press Release: Wilex Publishes Financial Report for the First Quarter of 2012. Rights Issue Successfully Concluded – Process for Final Analysis of Rencarex Started – Revenue and Earnings Improved". Munich. 2012-04-12
Wilex AG. (4/10/14). "Press Release: Wilex AG Plans Reduction of Share Capital. Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)". Munich. 2014-04-10
Wilex AG. (3/31/14). "Press Release: Wilex Announces Financial Figures for the 2013 Financial Year and Reports on Course of Business". Munich. 2014-03-31
next pagenext page 1 2 3 ... 170 171 172  next pagenext page


Picture [LSUS] – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top